Weight-based heparin protocol using antifactor Xa monitoring

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Internal Medicine

Background:

• Unfractionated heparin (UFH) is a critical anticoagulant requiring precise dosing.
• Therapeutic anticoagulation with UFH is typically monitored using activated partial thromboplastin time (aPTT) or antifactor Xa levels.
• Antifactor Xa monitoring offers a more specific measure of heparin's anticoagulant effect, especially in certain patient populations.

Purpose of the Study:

• To evaluate the efficacy of a weight-based dosing protocol for unfractionated heparin (UFH) infusions.
• To assess the performance of antifactor Xa monitoring in guiding UFH therapy.
• To determine the proportion of patients achieving target antifactor Xa levels within the initial 24 hours of UFH infusion.

Main Methods:

• A prospective analysis of the first 50 patients receiving UFH infusions for over 24 hours was conducted.
• Patients received a weight-based UFH bolus (26 units/kg) and continuous infusion (15 units/kg/hr).
• Antifactor Xa levels were monitored every 6 hours initially, then adjusted based on a target range of 0.3-0.7 unit/mL.

Main Results:

• 52% of patients achieved the target antifactor Xa level at 6 hours.
• 92% of patients reached the target range within 24 hours.
• In patients weighing over 100 kg, 94% achieved therapeutic levels within 24 hours.

Conclusions:

• The weight-based UFH dosing protocol, guided by antifactor Xa monitoring, is highly effective.
• This protocol ensures a high rate of therapeutic anticoagulation within the first 24 hours.
• The dosing strategy demonstrates particular success in managing anticoagulation in obese patients.